Enter the vial size and the bacteriostatic water you added to get the concentration and the syringe units for a quantity on a U-100 syringe. The defaults reproduce the 6 mg/mL strength of the approved 18 mg/3 mL generic, and the one liraglutide amount with a source is Saxenda's 3 mg — a prescription product. The compound itself is covered in the liraglutide guide.
An 18 mg vial of liraglutide reconstituted with 3 mL of bacteriostatic water gives a concentration of 6.0 mg/mL, or 60 mcg per unit on a U-100 syringe. For a 3 mg dose, draw the syringe to 50.0 units (0.50 mL). At that dose the vial provides about 6 doses.
Defaults: 18 mg in 3 mL reproduces the strength of the approved generic liraglutide 18 mg/3 mL (6 mg/mL); Peptigrity has no lab tests of liraglutide on file to take a vial size from. 3 mg is the Saxenda label dose, used here for arithmetic only.
Draw the syringe up to
That's one 3 mg dose. Add 3 mL of water to your 18 mg vial first.
Liraglutide has 0 independent lab tests on file at Peptigrity. There is therefore no purity figure to show for it, and none is implied by anything on this page: a calculator converts the mass on a label, it does not confirm it.
Liraglutide is an acylated GLP-1 receptor agonist, about 97% homologous to native human GLP-1, with a C16 fatty-acid chain that extends its half-life to about 13 hours for once-daily dosing. It is FDA-approved as Victoza (type 2 diabetes and cardiovascular risk reduction) and Saxenda (chronic weight management), and generic versions now exist. Research-market liraglutide is none of those products: it is sold for research use only and is not FDA-approved.
The table sets out what the compound page states (page last updated August 2026, read 21 September 2026), and at what level of evidence.
| Question | What the compound page states | Evidence level |
|---|---|---|
| What is it? | An acylated GLP-1 receptor agonist; half-life about 13 hours | FDA-approved (human clinical pharmacology) |
| Approved products? | Victoza (type 2 diabetes, cardiovascular risk reduction) and Saxenda (chronic weight management), Novo Nordisk | FDA-approved |
| A labelled amount? | Saxenda at 3 mg, for weight management | FDA label |
| How often, and how? | Once-daily injection | FDA label |
| A product strength? | Generic liraglutide 18 mg/3 mL, referencing Victoza, approved December 23, 2024 | FDA approval |
| A research-grade dose? | None — “Does Peptigrity recommend a Liraglutide dose? No.” | None — declined |
| Independent lab tests? | 0 on file | No purity data |
The compound page states 3 mg and no other liraglutide dose, so 3 mg is the only quantity on this page tied to a source; every other row in the tables below is arithmetic.
Peptigrity does not recommend a liraglutide dose. The table prints the two label figures the compound page states (last updated August 2026) and converts them at the page default of 6 mg/mL; the research-grade column is empty because no source states a dose for research material.
| Label figure | What it is | At 6 mg/mL (18 mg + 3 mL) | Research-grade liraglutide |
|---|---|---|---|
| 3 mg, once daily | Saxenda (chronic weight management), a prescription injection | 50 units (0.50 mL); an 18 mg vial holds 6 such quantities | — none stated |
| 18 mg in 3 mL | The strength of the first generic, referencing Victoza — a concentration (6 mg/mL), not a dose | 60 mcg per unit on a U-100 syringe | — none stated |
What the label figure did in its trial, as the compound page reports it: in the label's pivotal 56-week study, liraglutide 3 mg produced a −7.4% mean weight change versus −3.0% on placebo, with 62.3% versus 34.4% of patients losing at least 5% — modest relative to newer agents.
The table converts reference quantities to syringe units at the default of 6.0 mg/mL (18 mg of Liraglutide in 3 mL), and counts how many draws of each a vial holds. Every row is arithmetic, not a dose: read the units for the amount you already intend to measure.
| Quantity | Draw at 6.0 mg/mL | Volume | Draws from a 5 mg vial | Draws from a 18 mg vial |
|---|---|---|---|---|
| 250 mcg | 4.2 units | 0.042 mL | 20 | 72 |
| 500 mcg | 8.3 units | 0.083 mL | 10 | 36 |
| 1 mg | 16.7 units | 0.17 mL | 5 | 18 |
| 2 mg | 33.3 units | 0.33 mL | 2.5 | 9 |
| 3 mg | 50.0 units | 0.50 mL | 1.67 | 6 |
The same Liraglutide quantity lands on a different mark depending on how much water went into the vial. Read down the column for the concentration you actually mixed; a units figure carried across from another column is simply wrong.
| Quantity | At 9.0 mg/mL (18 mg + 2 mL) | At 6.0 mg/mL (18 mg + 3 mL) | At 3.0 mg/mL (18 mg + 6 mL) |
|---|---|---|---|
| 250 mcg | 2.8 units | 4.2 units | 8.3 units |
| 500 mcg | 5.6 units | 8.3 units | 16.7 units |
| 1 mg | 11.1 units | 16.7 units | 33.3 units |
| 2 mg | 22.2 units | 33.3 units | 66.7 units |
| 3 mg | 33.3 units | 50.0 units | 100.0 units |
Every cell is the same arithmetic: units = (quantity in mg ÷ concentration in mg/mL) × 100 on a U-100 syringe. More water spreads the same mass over more units, which is the fix when a small quantity would otherwise sit at two or three units, where a one-unit misread is a large error.
Each Liraglutide vial holds as many draws as its labelled mass divided by the quantity per draw; the water volume changes nothing about it. The grid counts draws, not weeks — the approved products are once-daily injections, per the liraglutide compound page; divide by your own frequency to get days.
| Vial size | At 250 mcg | At 500 mcg | At 1 mg | At 2 mg | At 3 mg |
|---|---|---|---|---|---|
| 5 mg | 20 | 10 | 5 | 2.5 | 1.67 |
| 18 mg | 72 | 36 | 18 | 9 | 6 |
The labelled mass is not a guarantee of the mass in your vial: net content is a separate measurement from purity, and with no independent tests of Liraglutide on file there is no measured figure to compare a label against.
The approved products are prescription injections dispensed by pharmacies; a research vial is the thing that needs water added, and no page on Peptigrity sets a diluent volume for research-grade liraglutide. The page default of 3 mL in an 18 mg vial was chosen because it reproduces the 18 mg/3 mL strength (6 mg/mL), so a units figure here reads the same as at that strength. The one tracked offer on the price record is a 5 mg vial: 3 mL in that vial gives 1.67 mg/mL, where 3 mg would be 180 units — more than a 1 mL barrel. Reproducing 6 mg/mL in a 5 mg vial takes 5 ÷ 6 = 0.83 mL; the calculator above does the same arithmetic for any vial and volume.
Technique and diluent choice are covered once, elsewhere, as general guidance rather than a liraglutide-specific finding: reconstituting peptides step by step and the bacteriostatic water guide.
The table repeats the compound page's comparison (US status as of August 2026). Each figure is that trial's own published result — different trials, durations and populations, not head-to-head comparisons.
| Compound | Regimen | Published weight-loss anchor | US status (Aug 2026) |
|---|---|---|---|
| Liraglutide (Saxenda 3 mg) | Once-daily injection | −7.4% vs −3.0% placebo at 56 weeks (label pivotal study) | FDA-approved; generics December 2024 (Victoza reference) and August 2025 (Saxenda reference) |
| Semaglutide (Wegovy 2.4 mg) | Once-weekly injection | −14.9% at 68 weeks (STEP 1) | FDA-approved |
| Tirzepatide (Zepbound) | Once-weekly injection | −16.0% to −22.5% by dose at 72 weeks (SURMOUNT-1) | FDA-approved |
| Retatrutide | Once-weekly injection (investigational) | −24.2% at 48 weeks (12 mg, Phase 2) | Not approved (Phase 3) |
The weekly agents have their own calculators: semaglutide, tirzepatide and retatrutide. The category page is weight loss & metabolic.
Liraglutide is FDA-approved as Victoza and Saxenda (and approved in the EU and UK), but products sold through research-chemical vendors are not the approved pharmaceutical and are marketed for research use only. The FDA approved the first generic of a once-daily GLP-1 injection — liraglutide 18 mg/3 mL, referencing Victoza — on December 23, 2024, and a first generic referencing Saxenda followed in August 2025. Generic liraglutide is a prescription-pharmacy product, not a research chemical. On April 30, 2026 the FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list; the comment period closed June 29, 2026 and no final rule had issued as of August 2026.
The label's safety record, as the compound page reports it: the most common effects are gastrointestinal (nausea, diarrhea, vomiting, constipation); documented serious risks include pancreatitis, gallbladder disease and a boxed warning for thyroid C-cell tumors, with a contraindication in a personal or family history of medullary thyroid carcinoma or MEN2.
Peptigrity has no independent lab tests of liraglutide, so there is no lab-test page to link and no purity figure to quote; the identity check a certificate would need is mass spectrometry against the expected molecular weight of about 3751 Da. Tracked prices, last read 21 September 2026: a single comparable offer, $10.20 per mg on a 5 mg vial — one offer is not a market price. See liraglutide price per milligram.
It depends on the concentration. At the page default of 6 mg/mL (18 mg in 3 mL, the strength of the 18 mg/3 mL generic), 3 mg is 50 units (0.50 mL) on a U-100 syringe. With 2 mL in the same vial (9 mg/mL) it is 33.3 units; with 6 mL (3 mg/mL) it is a full 100 units. A units figure quoted without a concentration cannot be used.
There isn't one for research-grade liraglutide, and Peptigrity does not recommend a dose. The one amount the compound page gives is the Saxenda label's 3 mg, a once-daily prescription injection for chronic weight management. Research-grade liraglutide sold for laboratory use is not an FDA-approved product.
Yes. The FDA approved the first generic of a once-daily GLP-1 injection, liraglutide 18 mg/3 mL referencing Victoza, on December 23, 2024, and a first generic referencing Saxenda followed in August 2025. Generic liraglutide is dispensed by prescription through pharmacies; it does not make research-market vials an approved product.
No. Peptigrity has 0 independent lab tests of liraglutide on file, so there is no purity figure for it. A certificate would need HPLC purity and a mass-spectrometry identity check against the expected molecular weight of about 3751 Da.
Both are GLP-1 receptor agonists, but liraglutide is injected once daily and is the earlier generation; semaglutide is once weekly with greater weight loss. In their own trials, Saxenda 3 mg gave a -7.4% mean weight change at 56 weeks (versus -3.0% on placebo) and Wegovy 2.4 mg gave -14.9% at 68 weeks. These are different trials, not a head-to-head comparison.